KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) EBITDA Margin: 2009-2024

Historic EBITDA Margin for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to -1.83%.

  • Teva Pharmaceutical Industries' EBITDA Margin rose 2086.00% to 19.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.89%, marking a year-over-year increase of 802.00%. This contributed to the annual value of -1.83% for FY2024, which is 456.00% down from last year.
  • According to the latest figures from FY2024, Teva Pharmaceutical Industries' EBITDA Margin is -1.83%, which was down 167.02% from 2.73% recorded in FY2023.
  • In the past 5 years, Teva Pharmaceutical Industries' EBITDA Margin registered a high of 10.81% during FY2021, and its lowest value of -21.44% during FY2020.
  • In the last 3 years, Teva Pharmaceutical Industries' EBITDA Margin had a median value of -1.83% in 2024 and averaged -4.61%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first surged by 3,225bps in 2021, then tumbled by 2,553bps in 2022.
  • Teva Pharmaceutical Industries' EBITDA Margin (Yearly) stood at -21.44% in 2020, then spiked by 3,225bps to 10.81% in 2021, then plummeted by 2,553bps to -14.72% in 2022, then surged by 1,745bps to 2.73% in 2023, then plummeted by 456bps to -1.83% in 2024.